PATRICK DEVAL L - 14 Jun 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc.

Role: Director
Signature: /s/ Miguel Carrillo, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 14 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 16 Jun 2022, 18:00:16 UTC
Previous filing: 15 Jun 2022
Next filing: 17 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GBT	Common Stock	Options Exercise		+3,600	+66%		9,037	14 Jun 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GBT	Restricted Stock Units	Options Exercise	$0	-3,600	-100%	$0.000000^*	0	14 Jun 2022	Common Stock	3,600		Direct	F1, F2
transaction	GBT	Stock Option (Right to Buy)	Award	$0	+5,600		$0.000000	5,600	14 Jun 2022	Common Stock	5,600	$22.30	Direct	F3
transaction	GBT	Restricted Stock Units	Award	$0	+3,600		$0.000000	3,600	14 Jun 2022	Common Stock	3,600		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2	The RSUs vested in a single installment on June 14, 2022.
F3	The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 14, 2022 for 11 months and the remaining 1/12th on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).
F4	The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).